



# Treatment of COVID-19: Hydroxychloroquine and Chloroquine

April 20, 2020

To date, the U.S. Food and Drug Administration (FDA) has not approved any therapeutics—drugs or biologics—for the treatment of COVID-19. However, FDA has authorized the emergency use of two drugs: hydroxychloroquine sulfate (“hydroxychloroquine”) and chloroquine phosphate (“chloroquine”). [The agency has determined](#) that based on the totality of scientific evidence, “it is reasonable to believe that [chloroquine] and [hydroxychloroquine] may be effective in treating COVID-19,” and that when used in accord with the conditions of the emergency use authorization (EUA), the known and potential benefits outweigh the known and potential risks of these drugs. [Some stakeholders—including several former FDA officials—have expressed concern](#) regarding FDA’s EUA, stating that current data regarding the safety and effectiveness of these drugs for treatment of COVID-19 are largely anecdotal and that expanding access may jeopardize research into the drug. When asked whether there is evidence that hydroxychloroquine may be effective as a prophylaxis against COVID-19, Dr. Anthony Fauci—Director of the National Institute of Allergy and Infectious Diseases (NIAID)—has said “[the answer is no](#)” and that with respect to hydroxychloroquine as a treatment “[\[w\]e still need to do the definitive studies to determine whether any intervention, not just this one, is truly safe and effective.](#)”

## FDA Regulation of Drugs

FDA, under the Federal, Food, Drug, and Cosmetic Act, regulates the safety and effectiveness of drugs. Generally, before a new drug may be marketed in the United States, the manufacturer must submit to FDA for approval a new drug application containing evidence of the drug’s safety and effectiveness, as derived from clinical studies. Under certain circumstances, such as a public health emergency, FDA may authorize the use of investigational, unapproved therapies.

On March 28, 2020, [FDA authorized the emergency use](#) of hydroxychloroquine—approved as an anti-inflammatory and antimalarial—and chloroquine—approved as an antimalarial. Neither drug is FDA-approved for treatment of COVID-19 (see [Table 1](#)), and the drugs’ mechanisms of action are not entirely known.

**Table I. FDA-Approved Hydroxychloroquine and Chloroquine**

	Hydroxychloroquine sulfate	Chloroquine phosphate
Approved uses	Rheumatoid Arthritis, Lupus, treatment and prevention of malaria	Extraintestinal parasites, treatment and prevention of malaria
Initial U.S. approval date	1955	1949
Brand-name, manufacturer	Plaquenil (Concordia)	Aralen (Sanofi), discontinued
Generic manufacturers	14	3

Source: FDA Orange Book, accessed April 20, 2020.

## Access and Shortages

Patients can generally access hydroxychloroquine and chloroquine in one of two ways. First, FDA-approved versions of these drugs may be dispensed by pharmacies pursuant to an off-label prescription from a licensed health care provider. Second, both of these drugs are available to patients through the Strategic National Stockpile (SNS)—including versions of chloroquine not approved by FDA—as authorized in [FDA’s EUA letter](#). The EUA specifically allows for chloroquine and hydroxychloroquine donated to the SNS by drug manufacturers and distributed to states to be used, pursuant to a prescription from a licensed health care provider, to treat adults and teenagers hospitalized with COVID-19 for whom a clinical trial is not available or participation is not feasible.

The EUA imposes certain conditions on health care systems and providers receiving the drugs from the SNS (e.g., requiring reporting of all serious adverse events and clinical outcomes), although it is not clear how these data are being tracked and analyzed. Under normal circumstances, health care providers are encouraged, but not required, to report adverse drug events to FDA. As such, in cases where these drugs are not provided from the SNS—for example, when these drugs are prescribed off-label by a licensed health care provider—adverse event and outcomes data may not be submitted to FDA.

Increased demand for these drugs, primarily due to an increase in their off-label prescribing, has resulted in shortages, particularly for patients who rely on them for their approved indications. As a result, [several states](#) have limited dispensing of these drugs for treatment of COVID-19. For example, in New York, Governor Cuomo issued an [executive order](#) restricting dispensing of these drugs, except when prescribed for an FDA-approved indication or as part of a state-approved clinical trial. Other states have limited the quantity dispensed when prescribed for treatment of COVID-19. FDA’s EUA authorizes the use of chloroquine and hydroxychloroquine from the SNS for treatment of COVID-19 only, not for other indications (e.g., Lupus).

While states generally regulate drug dispensing and prescribing, FDA is the federal agency tasked with preventing and mitigating drug shortages. FDA is [required](#) to maintain a public list of drugs that are in shortage. Hydroxychloroquine and chloroquine [both appear on this list](#), with the shortages attributed to increased demand. In response, FDA is [prioritizing review of generic versions of chloroquine and hydroxychloroquine](#), has [enabled compounding](#) (i.e., the process by which a physician or pharmacist makes a drug for an individual patient) of hydroxychloroquine, and is working with companies to assess their supply.

## State of Research

FDA’s EUA is based on “[limited in-vitro and anecdotal clinical data in case series](#)” derived largely from international studies. For example, [one study conducted in China](#) evaluated the antiviral efficiency of five drugs in a laboratory-based setting and found that chloroquine was effective in controlling COVID-19

infection in vitro (i.e., outside of a living organism). A [clinical study conducted in France](#) found that hydroxychloroquine was effective in reducing viral load in COVID-19 patients, particularly in combination with azithromycin—an antibiotic that treats various bacterial infections. However, [numerous limitations](#) have been identified regarding this small, nonrandomized study, such as how the data were collected and analyzed. Further, [results were mixed](#) regarding the effectiveness of hydroxychloroquine for treatment of COVID-19 based on other small, clinical studies conducted in China and France.

There are also concerns about the safety of these drugs for treatment of COVID-19, including appropriate dosing, possible drug interactions, and the [potential for adverse cardiac events](#) among certain patients. For example, a study in Brazil was [recently stopped](#) because some COVID-19 patients taking higher doses of chloroquine developed irregular heart rates that increased their risk of developing a fatal heart arrhythmia.

A broader question has been raised about a [cohesive research strategy](#) moving forward. As of April 20, 2020, there are [123 ongoing clinical trials](#) examining hydroxychloroquine or chloroquine for treatment of COVID-19, according to a [database](#) maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). With certain exceptions, such as one recently announced trial [funded by NIH](#), these trials are largely funded by the U.S. private sector or taking place internationally. However, many of the studies in the NLM database are in early stages—either recruiting or not yet recruiting patients—and there is some concern that off-label prescribing of these drugs may discourage patients from participating in such trials where there is a chance of receiving a placebo rather than the drug.

## Author Information

Agata Dabrowska  
Analyst in Health Policy

Victoria R. Green  
Analyst in Health Policy

---

## Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS's institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.